Tag: GlobeNewswire

ROCHESTER, NEW YORK, Nov. 02, 2026 (GLOBE NEWSWIRE) — Syntec Optics Holdings, Inc. (Nasdaq: OPTX), a leading provider of deep-tech space solutions, has secured a nearly 25% increase in orders for advanced space reconnaissance, building on a major program announced two months ago.

Dean Rudy, CFO, stated: “Our open capacity, increased profitability, and bank debt-free balance sheet allow us to scale unhindered. Alongside leading innovators, we can support increases in enduring U.S. government priorities for Earth imaging and sensing.”

Building on the 2019 pivot away from legacy mega-satellites, the multi-billion-dollar frameworks of 2021 established resilient, proliferated LEO constellations. Today, defense leaders are advancing this technology frontier further.

“Our team is excited to help drive forward the next steps in this cross-administration-backed seven-year vision,” added Rudy.  

Matt Carey, VP of Business Development, said, “For us, this marks the foundational stage of unlocking the limitless potential of space.”

With thousands of specialized optical laser links produced for commercial space-to-space communication, Syntec solidifies its role as a key partner in modern reconnaissance, secure satellite communications, orbital safety, and rocket launches.

About Syntec Optics

Headquartered in Rochester, N.Y., Syntec Optics Holdings, Inc. (NASDAQ: OPTX) is one of the nation’s largest bespoke makers of high-precision optics. It pushes the limits of light-based technologies to connect and protect the world. Syntec supports critical missions ranging from low-Earth-orbit satellites to advanced next-gen connected-battlefield defense platforms, moon rocket actuators, AI data centers, and life sciences. As light-enabled technologies continue to account for a significant portion of global economic output—representing nearly $20 trillion of the $111 trillion in total worldwide production as of 2024—Syntec Optics remains positioned at the forefront of the modern optical revolution.

For more information, visit syntecoptics.com.

Forward-Looking Statements

This press release contains certain “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact contained in this press release, including statements as to the intended use of net proceeds from the public offering, are forward-looking statements. Some of these forward-looking statements can be identified by the use of forward-looking words, including “may,” “should,” “expect,” “intend,” “will,” “estimate,” “anticipate,” “believe,” “predict,” “plan,” “targets,” “projects,” “could,” “would,” “continue,” “forecast” or the negatives of these terms or variations of them or similar expressions. All forward-looking statements are subject to risks, uncertainties, and other factors (some of which are beyond the control of Syntec Optics), which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. All forward-looking statements are based upon estimates, forecasts and assumptions that, while considered reasonable by Syntec Optics and its management, as the case may be, are inherently uncertain and many factors may cause the actual results to differ materially from current expectations which include, but are not limited to: 1) risk outlined in any prior SEC filings; 2) ability of Syntec Optics to successfully increase market penetration into its target markets; 3) the addressable markets that Syntec Optics intends to target do not grow as expected; 4) the loss of any key executives; 5) the loss of any relationships with key suppliers including suppliers abroad; 6) the loss of any relationships with key customers; 7) the inability to protect Syntec Optics’ patents and other intellectual property; 8) the failure to successfully execute manufacturing of announced products in a timely manner or at all, or to scale to mass production; 9) costs related to any further business combination; 10) changes in applicable laws or regulations; 11) the possibility that Syntec Optics may be adversely affected by other economic, business and/or competitive factors; 12) Syntec Optics’ estimates of its growth and projected financial results for the future and meeting or satisfying the underlying assumptions with respect thereto; 13) the impact of any pandemic, including any mutations or variants thereof and the Russian/Ukrainian or Israeli conflict, and any resulting effect on business and financial conditions; 14) inability to complete any investments or borrowings in connection with any organic or inorganic growth; 15) the potential for events or circumstances that result in Syntec Optics’ failure to timely achieve the anticipated benefits of Syntec Optics’ customer arrangements; and 16) other risks and uncertainties set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in prior SEC filings. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Syntec Optics does not give any assurance that Syntec Optics will achieve its expected results. Syntec Optics does not undertake any duty to update these forward-looking statements except as otherwise required by law.

For further information, please contact:

Investor Relations

InvestorRelations@syntecoptics.com 

SOURCE: Syntec Optics Holdings, Inc. (Nasdaq: OPTX)

DURHAM, N.C, Nov. 02, 2026 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that the Company will release its financial results for the three months and nine months ended September 30, 2026, on Tuesday, November 10, 2026. Management will host a webcast and conference call at 8:00 a.m. Eastern Time to provide a corporate and financial update.

Title	Humacyte 2026 Third Quarter Financial Results and Corporate Update
Date	November 10, 2026
Time	8:00 a.m. Eastern Time
Conference Details	1-877-704-4453 (U.S. Investors) 1-201-389-0920 (International Investors) 13763173 (Conference ID)
Call me™	Click Here
Webcast	Click Here

About Humacyte

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Humacyte’s Biologics License Application for Symvess, the acellular tissue engineered vessel (ATEV), in the vascular trauma indication was approved by the FDA in December 2024. ATEVs are also currently in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). The Company is preparing for human clinical study in coronary artery bypass graft surgery, and preclinical development is also underway in the treatment of type 1 diabetes, pediatric heart disease, and multiple novel cell and tissue applications. Humacyte’s 6mm ATEV for AV access in hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation. Humacyte’s 6mm ATEV for urgent arterial repair following extremity vascular trauma and for advanced PAD also have received RMAT designations. The ATEV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.

For uses other than the FDA approval in the extremity vascular trauma indication, the ATEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.

Forward-Looking Statements

This press release contains forward-looking statements that are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, our plans and ability to commercialize Symvess and, if approved by regulatory authorities, our product candidates, successfully and on our anticipated timelines; the degree of market acceptance of and the availability of third-party coverage and reimbursement for Symvess and, if approved by regulatory authorities, our product candidates; our ability to manufacture Symvess and, if approved by regulatory authorities, our product candidates in sufficient quantities to satisfy our clinical trial and commercial needs; the anticipated benefits of our ATEVs relative to existing alternatives; our plans and ability to execute product development, process development and preclinical development efforts successfully and on our anticipated timelines; our ability to design, initiate and successfully complete clinical trials and other studies for our product candidates and our plans and expectations regarding our ongoing or planned clinical trials; the anticipated characteristics and performance of our ATEVs; the implementation of our business model and strategic plans for our business; our ability to execute and achieve the expected benefits of our cost-saving measures and whether our efforts will result in further actions or additional asset impairment charges that adversely affect our business; and the timing or likelihood of regulatory filings, acceptances and approvals. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Humacyte may be adversely affected by other economic, business, competitive and/or reputational factors, and other risks and uncertainties, including those described under the header “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025 and Form 10-Q for the quarter ended June 30, 2026, each filed by Humacyte with the SEC, and in future SEC filings. Most of these factors are outside of Humacyte’s control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. Except as required by law, we have no current intention of updating any of the forward-looking statements in this press release. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

Humacyte Investor Contact:
Joyce Allaire
LifeSci Advisors LLC
+1-617-435-6602
jallaire@lifesciadvisors.com
investors@humacyte.com

Humacyte Media Contact:
Rich Luchette
Precision Strategies
+1-202-845-3924
rich@precisionstrategies.com
media@humacyte.com

MONTREAL and CHARLOTTE, N.C., Nov. 02, 2026 (GLOBE NEWSWIRE) — Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced new data showing that CARDAMYST® (etripamil) nasal spray converted approximately two-thirds of patients who experienced recurrent symptomatic paroxysmal supraventricular tachycardia (PSVT) after a prior catheter ablation to normal heart rhythm within 30 minutes. The subgroup analysis of the Phase 3 RAPID clinical trial will be presented by David Bharucha, MD, Ph.D., FACC, Chief Medical Officer of Milestone Pharmaceuticals in a moderated poster session at the American Heart Association (AHA) Scientific Sessions 2026 on Saturday, November 7. CARDAMYST is FDA-approved for the conversion of acute symptomatic episodes of PSVT to sinus rhythm in adults.

“Most patients do well after ablation but a subset continues to have episodes, and we have had limited options to offer them for treating an episode outside of an emergency room setting,” said James E. Ip, MD, Professor of Medicine and Director of Cardiac Pacing and Implantable Devices at Weill Cornell Medicine, a cardiac electrophysiologist at New York-Presbyterian/Weill Cornell Medical Center, and lead author of the analysis. “These data, although from a small group, are encouraging because the response to etripamil nasal spray in patients with a prior ablation is similar to what we observed across the broader RAPID population. For patients considering a repeat procedure, having a self-administered option to treat an episode should be a meaningful part of the conversation they have with their cardiologist.”

Catheter ablation is a procedure intended to treat PSVT, a common type of rapid heart rhythm, and it is successful for most patients. A small proportion of patients continue to have episodes afterward, and treatment options for these patients are limited.

Data Highlights

• Prior ablation was reported in 6.6% of all randomized patients (46 of 692) in RAPID and in 6.0% of those with adjudicated, confirmed PSVT in the efficacy population (11 of 184), confirming that a subset of patients continue to experience confirmed PSVT recurrences after ablation.
• In the prior-ablation subgroup (N=11), 66.7% of etripamil-treated patients (n=6) converted to sinus rhythm at 30 minutes, compared with 20.0% of placebo-treated patients (n=5), consistent with the conversion observed in the overall RAPID efficacy population. These are descriptive data, and this subgroup analysis was not powered for between-group comparison.
• Safety in the prior-ablation subgroup was assessed using continuous ECG recordings and adverse-event reporting, including monitoring for AV block and prolonged pauses.

The authors concluded that etripamil should be considered a potential treatment option for patients who have incomplete resolution after ablation or who are considered high risk for a repeat procedure.

“In this analysis from the RAPID trial, patients with recurrent PSVT after a prior ablation responded to etripamil in a manner consistent with the overall trial population,” said David Bharucha, MD, Ph.D., FACC. “Thus, we believe these findings reinforce the overall data which show etripamil to be a safe and effective treatment option, and support this drug to be used as a self-administered treatment for patients who may have continued episodes of PSVT after ablation.”

The subgroup analysis draws on the overall RAPID trial, which met its primary endpoint. In the prior-ablation efficacy subgroup (N=11), patients had a mean age of 50.9 years, 82% were female, and 54.5% were taking an oral AV nodal-acting medication. Six patients received etripamil and five received placebo.

RAPID (NCT03464019) was a randomized, double-blind, event-driven, placebo-controlled Phase 3 study evaluating a single or repeat 70 mg dose of etripamil, self-administered by patients during a perceived PSVT episode, with a repeat dose permitted per protocol. Episodes were adjudicated from ambulatory ECG recordings. The efficacy population included patients who self-administered study drug during an adjudicated, confirmed, AV nodal-dependent PSVT episode; patients with post-conversion dosing, non-AV nodal-dependent events, or substantial ECG signal loss were excluded. To enroll, patients with a prior PSVT ablation were required to have documented ECG evidence of recurrent PSVT after the procedure.

CARDAMYST Product Theater

Milestone will also host a Product Theater at AHA Scientific Sessions 2026 titled “How Can CARDAMYST, the first and only FDA-approved, self-administered treatment for PSVT in adults, be used in a Health Care Professional’s practice?” on Saturday, November 7, from 9:30 to 10:15 am CT. The presenter will be Matthew Budoff, MD, FACC, FAHA, of the Department of Medicine, Lundquist Institute at Harbor-UCLA.

About CARDAMYST 

CARDAMYST^® (etripamil) nasal spray is approved by the U.S. Food and Drug Administration (FDA) for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. It is a novel calcium channel blocker nasal spray designed as a self-administered rapid response therapy for patients, thereby bypassing the need for immediate medical oversight. The product is intended to provide health care providers with a new treatment option to enable on-demand care and patient self-management. This portable treatment may provide patients with active management and a greater sense of control over their condition. CARDAMYST is well studied with a robust clinical trial program that includes a completed Phase 3 clinical-stage program for the treatment of PSVT. Currently, etripamil is in Phase 2 development for treatment of PSVT in pediatric patients and Phase 3 development for control of acute atrial fibrillation with rapid ventricular rate (AFib-RVR) in adults. For more information, please visit CARDAMYST.com. 

U.S. FDA Indication
CARDAMYST is indicated for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.

IMPORTANT SAFETY INFORMATION FOR CARDAMYST (etripamil)

What is CARDAMYST?

CARDAMYST is a prescription medicine used to help restore normal sinus heart rhythm in adults who have symptoms of sudden episodes of fast heartbeat called paroxysmal supraventricular tachycardia (PSVT).

It is not known if CARDAMYST is safe and effective in children.

Do not use CARDAMYST if you:

• are allergic to CARDAMYST or any of its ingredients. See the Patient Information for a complete list of ingredients in CARDAMYST.
• have limitations in activities due to heart failure (moderate to severe heart failure).
• have Wolff-Parkinson-White (WPW) syndrome, Lown-Ganong-Levine syndrome, or an abnormal heart rhythm pattern called pre-excitation (delta wave) on an electrocardiogram (ECG).
• have sick sinus syndrome without a permanent pacemaker.
• have second degree or higher atrioventricular (AV) block.

Before using CARDAMYST, tell your healthcare provider about all of your medical conditions, including if you:

• have a history of fainting.
• have low blood pressure.
• are pregnant or plan to become pregnant. It is not known if CARDAMYST will harm your unborn baby.
• are breastfeeding or plan to breastfeed. It is not known if CARDAMYST passes into your breast milk. You should stop breastfeeding for 12 hours after treatment with CARDAMYST. During this time, pump and throw away your breast milk. Talk to your healthcare provider about the best way to feed your baby after using CARDAMYST.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of CARDAMYST?

CARDAMYST may cause serious side effects, including:

• Fainting due to CARDAMYST effects on blood pressure, heart rate, and electrical activity of the heart. CARDAMYST may cause dizziness and fainting, especially in people with a history of fainting and certain heart problems, or people with a history of fainting during an episode of PSVT. Use CARDAMYST while sitting in a safe area where you will not fall if you become dizzy or lightheaded. Lie down if you feel dizzy or lightheaded after using CARDAMYST. If fainting occurs after using CARDAMYST, caregivers should place you on your back and seek medical help.

The most common side effects of CARDAMYST include nasal discomfort, nasal congestion, runny nose, throat irritation, and nosebleed.

These are not all of the possible side effects for CARDAMYST. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Please see the full Prescribing Information 
https://milestonepharma.com/etripamilprescribinginformation.pdf for CARDAMYST.

About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is an emerging commercial-stage biopharmaceutical company advancing innovative cardiovascular medicines to benefit people living with certain heart conditions. Milestone’s lead product is CARDAMYST® (etripamil) nasal spray, a novel calcium channel blocker, which is FDA-approved for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. Etripamil is also in Phase 3 development for the control of symptomatic episodic attacks associated with AFib-RVR. https://milestonepharma.com/.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “continue,” “could,” “demonstrate,” “designed,” “develop,” “estimate,” “expect,” “may,” “pending,” “plan,” “potential,” “progress,” “will,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Milestone’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include statements regarding: Milestone’s business strategy and plans; the commercialization and market adoption of CARDAMYST; expectations regarding the potential role of CARDAMYST as a self-administered treatment option for patients experiencing recurrent PSVT after catheter ablation; the anticipated presentations at AHA Scientific Sessions 2026; Milestone’s development plans for etripamil in additional indications and patient populations; and other statements not related to historical facts. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, the risks inherent in biopharmaceutical product development and clinical trials, including the lengthy and uncertain regulatory approval process; uncertainties related to the timing of initiation, enrollment, completion, evaluation and results of Milestone’s clinical trials; risks and uncertainty related to the complexity inherent in cleaning, verifying and analyzing trial data; and whether the clinical trials will validate the safety and efficacy of etripamil for PSVT or other indications, among others, general economic, political, and market conditions, including deteriorating market conditions due to investor concerns regarding inflation, international tariffs and conflicts, and overall fluctuations in the financial markets in the United States and abroad, risks related to pandemics and public health emergencies, and risks related to the sufficiency of Milestone’s capital resources and its ability to raise additional capital in the current economic climate. These and other risks are set forth in Milestone’s filings with the U.S. Securities and Exchange Commission (SEC), including in its annual report on Form 10-K for the year ended December 31, 2025, and its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, under the caption “Risk Factors,” as such discussions may be updated from time to time by subsequent filings Milestone may make with the SEC. Except as required by law, Milestone assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Contact:

Investor Relations
Kevin Gardner, kgardner@lifesciadvisors.com

Media Relations
Rebecca Novak, rnovak@milestonepharma.com 

CALABASAS, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing therapies for central nervous system (CNS) cancers, today announced that data from its intranasal NEO100 and oral NEO212 programs will be presented in two posters on Friday, November 13, at the 31st Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO), held November 12 to 15, 2026, at the Pennsylvania Convention Center in Philadelphia.

“We look forward to presenting data from both of our clinical programs at SNO,” said Amir F. Heshmatpour, Executive Chairman, President and Chief Executive Officer of NeOnc. “These presentations reflect the progress we are making in bringing new approaches to patients with brain cancer.”

Presentation Details

Title: Durable Radiographic Remission and Prolonged Survival with Intranasal NEO100 in Recurrent WHO Grade III/IV IDH1-Mutant Astrocytoma: Updated Results from a Phase 1/2a Study and Compassionate Use Experience
Abstract Number: CTNI-26
Presentation Type: Poster
Session: Poster Session
Presenter: Thomas C. Chen, MD, PhD, University of Southern California and NeOnc Technologies Holdings, Inc.
Date and Time: Friday, November 13, 2026, 7:30 to 9:30 p.m. EST
Location: Exhibit Halls D and E, Second Floor, Pennsylvania Convention Center, Philadelphia

Title: Oral NEO212 in TMZ-Resistant Recurrent GBM and Brain Metastases: Phase 1 Safety, PK, and Early Signals of Activity
Abstract Number: CTNI-27
Presentation Type: Poster
Session: Poster Session
Presenter: Josh Neman, PhD, University of Southern California and NeOnc Technologies Holdings, Inc.
Date and Time: Friday, November 13, 2026, 7:30 to 9:30 p.m. EST
Location: Exhibit Halls D and E, Second Floor, Pennsylvania Convention Center, Philadelphia

About NEO100

NEO100 is a highly purified form of perillyl alcohol administered intranasally. Its delivery approach is designed to provide a non-invasive route to the brain. NEO100 remains investigational, and its safety and efficacy have not been established.

About NEO212

NEO212 is an investigational oral conjugate of temozolomide and NEO100. It is being studied for CNS cancers, including recurrent glioblastoma. Preclinical studies support further evaluation of its potential activity and delivery characteristics; clinical efficacy and safety have not been established. NEO212 is being developed under an FDA investigational new drug application.

About NeOnc Technologies Holdings, Inc.

NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company developing therapies for central nervous system cancers. Its investigational programs include intranasal NEO100 and oral NEO212. NEO212 has completed Phase 1 dose escalation and is advancing toward Phase 2 development. NeOnc exclusively licenses a worldwide portfolio of issued patents and pending applications from the University of Southern California related to NEO100, NEO212 and other drug candidates and delivery approaches.

For more information, visit https://neonc.com. 

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the Company’s clinical development programs and the clinical potential of NEO100. Forward-looking statements in this release also include statements regarding the clinical potential of NEO212 and the planned presentation of data at the Society for Neuro-Oncology Annual Meeting. These statements reflect current expectations and involve risks and uncertainties. NEO100 is investigational and has not been approved by any regulatory authority; future studies may not demonstrate safety or efficacy; clinical development remains subject to applicable clinical, regulatory and institutional requirements; and no regulatory pathway or marketing approval is assured. NEO212 is also investigational and has not been approved by any regulatory authority. Actual results may differ materially. Readers should consider the risk factors described in the Company’s most recent filings with the Securities and Exchange Commission. These statements speak only as of the date of this release.

The Company undertakes no obligation to update forward-looking statements except as required by law.

“NEO100” and “NEO212” are registered trademarks of NeOnc Technologies Holdings, Inc.

Contacts

Company Contact:
info@neonc.com 

Investor Contact:
Jon Nugent
Jon Nugent Communications
jon@jonnugent.com 
205-566-3026

This press release was published by a CLEAR® Verified individual.

Independent laboratory results advance first commercial waste-to-methanol module toward Portugal deployment

HOUSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) — HyOrc Corporation (OTCQB: HYOR) announced independent laboratory results from its first commercial module, demonstrating exceptionally low nitrogen dilution in refuse-derived fuel (RDF) syngas.

Prewel Laboratories measured 39.88% carbon monoxide, 35.55% hydrogen and 0.76% nitrogen after gasification and gas cleaning, before water-gas shift reaction, membrane separation and stoichiometric conditioning for methanol synthesis.

“Nitrogen is the number I’d look at,” said Reginald Fubara, CEO. “Air contains approximately 78% nitrogen, which conventional air-blown gasification carries into syngas. Our equipment produced just 0.76% nitrogen, alongside 75.43% combined hydrogen and carbon monoxide. That’s a significant achievement.”

Low nitrogen dilution can improve downstream efficiency and reduce equipment requirements.

HyOrc’s earlier pilot system (1 TPD RDF to 300 litres methanol daily) operated extensively before undergoing a structured 60-day monitoring and data-validation programme, including instrumentation upgrades to meet Bureau Veritas verification requirements. Bureau Veritas conducted three days of continuous on-site monitoring in April 2026, reporting satisfactory results with no non-conformities. Building on sustained pilot-scale methanol production, these latest results demonstrate the performance of HyOrc’s first commercial gasification module ahead of long-term operating validation in Portugal.

Portugal Deployment

The gasifier, tar-scrubbing and filtration systems are built. Final integration and factory testing are targeted for early December, followed by shipment to Portuguese JV partner MO.RE.DA. Oils, Lda., near Porto.

HyOrc has revised its deployment timetable to accommodate final equipment integration, factory testing and international shipping logistics, with initial methanol production in Portugal now targeted for Q1 2027.

“Our pilot system has already demonstrated sustained methanol production from waste,” said Mr Fubara. “We are now bringing that experience into our first commercial installation in Portugal, where the focus will be on demonstrating reliable, sustained production under everyday operating conditions.”

The initial module targets 3 tonnes of RDF daily, yielding approximately 1 tonne of methanol. A planned 35-tonne RDF expansion targeting 8 tonnes of methanol daily has an approved €6,706,550 non-repayable COMPETE 2030 STEP grant.

About HyOrc

HyOrc Corporation (OTCQB: HYOR) develops modular waste-to-methanol and power-generation technologies.

Website: www.hyorc.com Press Contact: comms@hyorc.com

Forward-Looking Statements

This release contains forward-looking statements concerning deployment, financing, commissioning, production and expansion. Actual results may differ due to funding, manufacturing, logistics, regulatory and operational risks. HyOrc undertakes no obligation to update these statements except as required by law.

ZUG, Switzerland and BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), today announced the appointment of Sivakesava (Siva) Sakhamuri, Ph.D., as Chief Technical Officer, effective immediately. Dr. Sakhamuri brings about 30 years of technical operations and manufacturing leadership experience across biologics, vaccines, oligonucleotides, RNA therapeutics and lipid nanoparticle (LNP) delivery.

“Siva has tremendous experience advancing novel therapies across various modalities into the clinic all the way through commercial stage, with expertise spanning biologics, RNA therapeutics and vaccines,” said Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer of CRISPR Therapeutics. “It is exciting to have Siva join our leadership team as we advance both our gene editing and RNA therapies into late-stage clinical development.”

“CRISPR Therapeutics has built a broad pipeline and strong in-house manufacturing capabilities, and I am excited to join at this stage of the Company’s growth,” said Dr. Sakhamuri. “I look forward to working with the talented team to scale our technical operations and manufacturing organization as we work to bring these investigational therapies to patients.”

Dr. Sakhamuri joins CRISPR Therapeutics from Orna Therapeutics, where he served as Chief Technical Officer since 2024, leading the CMC and quality organizations supporting the company’s circular RNA LNP programs through its acquisition by Eli Lilly and Company in 2026. Previously, he served as Senior Vice President and Head of Technical Operations and Quality at Omega Therapeutics, where he built the process development, analytical development, manufacturing, supply chain and quality functions and supported the company’s first Investigational New Drug (IND) application and Clinical Trial Application (CTA) clearances for an mRNA LNP program. From 2016 to 2021, he was Vice President, Manufacturing at Alnylam Pharmaceuticals, where he led CMC readiness for the commercial launch of three RNA interference (RNAi) therapeutics, oversaw internal and external manufacturing operations, and managed the construction of an internal oligonucleotide manufacturing facility.

Earlier in his career, Dr. Sakhamuri held leadership roles of increasing responsibility at Alexion Pharmaceuticals, where he led global technology transfer, technical services, and process and analytical development functions; Sanofi Pasteur, where he managed a commercial vaccine manufacturing operations; and Bristol Myers Squibb, where he held roles in biologics process development and manufacturing. Over his career, he has managed or supported 10 Biologics License Application (BLA) and New Drug Application (NDA) submissions and nine IND applications, and contributed to eight product launches. Dr. Sakhamuri received his Ph.D. in Biochemical Engineering from the Indian Institute of Technology, Chennai.

About CRISPR Therapeutics
CRISPR Therapeutics is a leading biopharmaceutical company focused on developing transformative gene-based medicines for serious human diseases. Founded over a decade ago as an early pioneer in CRISPR/Cas9 gene editing, the Company has evolved from a pioneering research-stage organization into an industry leader, marking a historic milestone with the approval of CASGEVY^® (exagamglogene autotemcel [exa-cel]), the world’s first CRISPR-based therapy, for eligible patients with sickle cell disease and transfusion-dependent beta thalassemia. Today, CRISPR Therapeutics is advancing a broad, diversified pipeline spanning hemoglobinopathies, cardiovascular disease, autoimmune disease, oncology, regenerative medicine and rare diseases. The Company is also expanding its gene editing toolkit through SyNTase^™ editing, its novel, proprietary platform designed to enable precise, efficient, and scalable gene correction. To accelerate its impact, CRISPR Therapeutics has established strategic collaborations with leading biopharmaceutical partners, including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California. To learn more, visit www.crisprtx.com.

Investor Contact:
+1-617-307-7503
ir@crisprtx.com

Media Contact:
+1-617-315-4493
media@crisprtx.com

VANCOUVER, British Columbia, Nov. 02, 2026 (GLOBE NEWSWIRE) — General Fusion Group Ltd. (NASDAQ: GFUZ) (“General Fusion” or the “Company”), a leader in the global race to commercialize fusion energy, today announced it will release its financial results and provide business updates for the third quarter of 2026 after market close on Monday, November 16, 2026, followed by a conference call at 5:00 p.m. Eastern Time.

A live webcast of the call can be accessed by visiting the Events & Presentations page of General Fusion’s investor relations website. Participants who wish to join by phone and ask questions during the Q&A may register here to receive dial-in details and a unique PIN.

A replay of the webcast will be available for 12 months on the Events & Presentations page of General Fusion’s investor relations website.

About General Fusion 
General Fusion (NASDAQ: GFUZ) is a fusion technology development company. The Company aims to deliver economical, carbon-free fusion energy through its practical Magnetized Target Fusion (“MTF”) technology, an engineering-driven approach to fusion energy. General Fusion’s commercialization program is anchored by LM26, the world’s first commercially relevant-scale MTF demonstration machine. The Company is working toward the commercial deployment of fusion power in the mid-2030s. General Fusion is the first publicly listed fusion company and TIME’s No. 1 GreenTech Company of 2026. For more information, visit generalfusion.com or follow General Fusion on LinkedIn, YouTube, and X. 

Investor Relations Contact 
Contact General Fusion’s Investor Relations team at: investors@generalfusion.com. 
If you are based in North America, you may also leave a toll-free voicemail at +1 (833) 717-1519. Callers outside North America can reach us at +1 (236) 253-6968.  

Media Relations Contact 
media@generalfusion.com  
1-866-904-0995

Cautionary Note Regarding Forward-Looking Statements 

This communication includes “forward-looking statements” within the meaning of the U.S. federal securities laws and “forward looking information” within the meaning of applicable Canadian securities laws (collectively, “forward-looking statements”). All statements other than statements of historical facts contained herein are forward-looking statements. Any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are also forward-looking statements. In some cases, you can identify forward-looking statements by words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “expect,” “anticipate,” “believe,” “seek,” “strategy,” “future,” “opportunity,” “may,” “target,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” “preliminary,” or similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements include, without limitation, statements regarding its ability to commercialize Magnetized Target Fusion (“MTF”) or any other fusion technology on its expected timeline or at all; statements regarding the current and expected results of the LM26 program, the Company’s plan to operate a first-of-a-kind plant around 2035; statements regarding the expected market opportunity for fusion energy, as well as any information concerning possible or assumed future results of operations or financial position of the Company.

These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. These forward-looking statements involve a number of risks, uncertainties that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that prior results are not successfully repeated on a larger scale; the risk that the scientific and technical assumptions underlying the results described herein prove to be incorrect; the risk that recent technical results do not prove to be as significant to the operation of LM26 as expected; the risk that the anticipated cost of funding the LM26 program across several planned technical milestones through the end of 2028 is greater than anticipated and additional capital needed by the Company may not be raised on favorable terms, or at all, including as a result of the restrictions agreed to in connection with the private placement the Company closed on July 10, 2026; the risk of adverse changes in general economic, financial market and geopolitical conditions, including conditions affecting capital markets and the clean energy sector; the risk that we are unable to develop, demonstrate and commercialize MTF technology on the expected timeline or at all, including any failure to achieve the balance of technical objectives of the LM26 program; the risk that we are unable to begin operating a first-of-a-kind plant around 2035, or at all; the risk that fusion energy does not gain public acceptance, the risk that the scientific and technical assumptions upon which the Company’s MTF technology is based do not prove to be correct, risks associated with the Company’s status as a development-stage company with a history of losses, no revenue from commercial fusion energy operations and no assurance of achieving profitability; the risk that our competitors develop viable fusion technology sooner than we do, the risk of supply chain disruptions, the risk that key technical material and service inputs may not be available when required on reasonable terms or at all, the risk that we are unable to attract and retain qualified personnel with highly technical expertise, the risk that we are subject to negative publicity, the risk that our assessment of the total addressable market for fusion energy is incorrect, the risk of changes in the laws and regulations governing the Company’s research and development activities and in the regulation of fusion energy generally; the risk of fluctuations in foreign currency exchange rates, particularly fluctuations in the Canadian dollar relative to the U.S. dollar; the risk that the Company is unable to complete and successfully integrate any future acquisitions; the risk of increased competition from other fusion energy companies and from other clean energy, conventional energy and energy storage technologies; the risk of accidents, earthquake, fires, floods and other natural disasters, the risk that our information technology fails, the risk that our operating expenses are materially higher than forecast, the risk that we are unable to remediate material weaknesses in our internal controls or identify additional material weaknesses in the future, the risk that we are unable to adequately protect or enforce our intellectual property rights, the risk of third party claims that we are infringing or violating another person’s intellectual property rights, the risk that our intellectual property applications are not granted, the risk of a cyber event or privacy breach resulting in an interruption in operations or financial loss, the risk that the trading in our securities may be volatile due to limited volume and the release of a substantial number of Subordinate Voting Shares from a lock-up expiring 180 days after the closing date of our business combination in July 2026; the risk of substantial dilution upon a reduction in the exercise or conversion price of the Multiple Voting Shares and PIPE warrants issued in July 2026 in accordance with the terms thereof; the effectiveness of our internal controls and disclosure controls and procedures; risks arising as a result from the limited experience of certain members of our management team in operating a public company; the risk that the period during which we will qualify as an emerging growth company under the JOBS Act is reduced; and the risk of litigation, governmental or regulatory proceedings, investigations or inquiries.

The foregoing list is not exhaustive, and there may be additional risks that the Company does not know or currently believes are immaterial. You should carefully consider the foregoing factors, any other factors discussed herein and in the other filings by the Company with the U.S. Securities and Exchange Commission including those described under the heading “Risk Factors.” If any of these risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements.

These forward-looking statements are based on a number of estimates and assumptions that we believe are reasonable when made including but not limited to: that none of the risks identified above materialize; that there are no unforeseen changes to economic and market conditions, and that no significant events occur outside the ordinary course of business. 

In addition, these statements reflect the expectations, plans, and forecasts of the Company’s management as of the date of this communication; subsequent events and developments may cause their assessments to change. While the Company may elect to update these forward-looking statements at some point in the future, they specifically disclaim any obligation to do so, unless required by applicable securities laws. Accordingly, undue reliance should not be placed upon these statements.

In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this communication, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements.

Not for distribution to United States Newswire Services or for dissemination in the United States

VANCOUVER, British Columbia, Nov. 02, 2026 (GLOBE NEWSWIRE) — Brixton Metals Corporation (TSX- V: BBB, OTCQX: BBBXF) (the “Company” or “Brixton”) is pleased to announce that it has closed a first tranche of a non-brokered private placement offering (the “Offering”) of national flow-through shares in the capital of Brixton (the “FT Shares”) and critical mineral flow-through shares in the capital of Brixton (the “CMFT Shares”). In connection with closing the first tranche of the Offering, the Company has issued 1,323,545 FT Shares at a price of $0.68 per FT Share and 4,978,874 CMFT Shares at a price of $0.71 per CMFT Share, for combined gross proceeds of $4,435,011.14.

The gross proceeds from the sale of FT Shares will be used to incur “Canadian exploration expenses” and “flow-through mining expenditures” as defined in the Income Tax Act (Canada) (the “Act”). The gross proceeds from the CMFT Shares will be used to incur “flow-through critical mineral mining expenditures” as defined in subsection 127(9) of the Act. Exploration expenditures are mainly for exploration and drilling at the Company’s Thorn Copper-Gold Project in British Columbia and the Langis Silver-Cobalt Project in Ontario.

In connection with the Offering, the Company paid $54,000.60 and issued 79,412 non-transferable common share purchase warrants (each, a “Compensation Warrant”) to arm’s length parties who assisted in introducing subscribers to the Offering. Each Compensation Warrant is exercisable to acquire one common share in the capital of the Company at an exercise price of $0.68 until October 30, 2028.

All securities issued in connection with the Offering are subject to a hold period of four months and one day expiring on March 1, 2027 pursuant to applicable Canadian securities laws. The Company intends to complete a further tranche of the Offering and will provide additional details once complete.

A director of the Company participated in the Offering in the amount of 49,295 CMFT Shares. Participation in the Offering by an insider of the Company constitutes a “related party transaction” within the meaning of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”). The issuance of securities to the insider of the Company is exempt from the valuation and minority shareholder approval requirements of MI 61-101 by virtue of the exemptions contained in sections 5.5(a) and 5.7(1)(a) of MI 61-101, respectively, on the basis that the fair market value of the consideration of the securities issued to the insider of the Company does not exceed twenty-five percent of the Company’s market capitalization, calculated in accordance with MI 61-101. The Company did not file a material change report at least 21 days in advance of the closing of the Offering as the participation of such director in the Offering had not been confirmed at that time.

About Brixton Metals Corporation

Brixton Metals is a Canadian exploration company focused on advancing its mining projects. Brixton wholly owns five exploration projects: the Langis and Hudson Bay silver Projects in Ontario; the Thorn copper-gold-silver-molybdenum Project in NW British Columbia; the Hog Heaven copper-silver-gold Project in NW Montana, USA, which is optioned to Ivanhoe Electric Inc.; and the Atlin Goldfields Project in northwest BC. Brixton holds an option to acquire a 100% interest in the silver-focused Silvergruvan Project in Sweden. Brixton Metals Corporation shares trade on the TSX-V under the ticker symbol BBB, and on the OTCQX under the ticker symbol BBBXF. For more information about Brixton, please visit our website at www.brixtonmetals.com.

On Behalf of the Board of Directors

Mr. Gary R. Thompson, Chairman and CEO
info@brixtonmetals.com

For Investor Relations inquiries, please contact: Mr. Michael Rapsch, Vice President Investor Relations. email: michael.rapsch@brixtonmetals.com or call Tel: 604-630-9707.

Follow us on:
LinkedIn | Twitter/X | Facebook | Instagram

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

Information set forth in this news release may involve forward-looking information under applicable securities laws. Forward-looking information are statements and information that relate to future, not past, events. In this context, forward-looking information often addresses expected future business and financial performance, and often contains words such as “anticipate”, “believe”, “plan”, “estimate”, “expect”, and “intend”; information and statements that an action or event “may”, “might”, “could”, “should”, or “will” be taken or occur, or other similar expressions. All information other than information of historical fact included herein are forward-looking information, including, without limitation, information regarding the Company’s business plans and strategies of operations; completion of a further tranche of the Offering; and use of proceeds of the Offering. By its nature, forward-looking information involves known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking information. Such factors include, among others, the following risks: the need for additional financing; operational risks associated with mineral exploration; fluctuations in commodity prices; title matters and the additional risks identified in the annual information form of the Company or other reports and filings with the TSXV and applicable Canadian securities regulators. Forward-looking information is based on management’s beliefs, estimates and opinions on the date that such information is provided and the Company undertakes no obligation to update forward-looking information if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable securities laws. Investors are cautioned against attributing undue certainty to forward-looking information. Brixton does not undertake to update any forward-looking information except in accordance with applicable securities laws.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws, unless an exemption from such registration is available.

FLORHAM PARK, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the company will report financial results for the third quarter ended September 30, 2026, and provide a corporate update on November 10, 2026, at 8:30 a.m. Eastern Time.

Conference Call & Webcast Details:
Date:	Tuesday, November 10, 2026
Time:	8:30 am Eastern Time
Toll Free:	1-800-717-1738
Conference ID: Webcast:	29257 Click HERE

A replay of the corporate presentation will be available on the Events section of the company’s Investor Relations website.

About Cellectar Biosciences, Inc.
Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects.

The company’s product pipeline includes iopofosine I 131, which is a PDC designed to provide targeted delivery of iodine-131 (radioisotope). Iopofosine I 131 has been tested in Phase 2b trials as a treatment for relapsed or refractory Waldenström macroglobulinemia (WM), in relapsed or refractory multiple myeloma (MM) and central nervous system (CNS) lymphoma. The CLOVER-2 Phase 1b study is evaluating iopofosine I 131 in pediatric patients with high-grade gliomas, for which Cellectar is eligible to receive a Pediatric Review Voucher from the FDA upon approval. The FDA has granted iopofosine I 131 Breakthrough, six Orphan Drug, four Rare Pediatric Drug and two Fast Track Designations for various cancer indications, and the EMA has granted iopofosine I 131 PRIority MEdicines (PRIME) designation.

Cellectar is also developing CLR 121125 (CLR 125), an iodine-125 Auger-emitting program targeted for solid tumors, such as triple negative breast (TNBC), lung, and colorectal cancer, and is currently being evaluated in a Phase 1b study for TNBC, which will determine the recommended dose for the subsequent Phase 2 trial. CLR 125 has been well tolerated in vivo and has demonstrated strong preclinical data showing reduction or inhibition of solid tumor growth.

In addition to these assets, the Cellectar team is developing CLR 121225 (CLR 225), an actinium-225 based program targeting solid tumors in indications with significant unmet need, such as pancreatic cancer, as well as proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets.

For more information, please visit https://www.cellectar.com/or join the conversation by liking and following us on the company’s social media channels: X, LinkedIn, and Facebook.

Investor Contact:
Anne Marie Fields
Precision AQ
212-362-1200
annemarie.fields@precisionaq.com

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following investor conferences in November.

Guggenheim 3^rd Annual Healthcare Innovation Conference
Date: Monday, November 9, 2026
Fireside Chat: 3:30 p.m. ET
Location: Boston, MA

Jefferies Global Healthcare Conference in London
Date: Wednesday, November 18, 2026
Fireside Chat: 8:30 a.m. GMT
Location: London, UK

A live webcast of the presentation will be available on the Events and Presentations page of CytomX’s website at www.cytomx.com. In addition, management will be available for one-on-one meetings with investors who are registered to attend the conferences.

About CytomX Therapeutics, Inc.
CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated, masked PROBODY^® therapeutics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered by its PROBODY therapeutic platform, CytomX’s vision is to create safer, more effective therapies for the treatment of cancer. CytomX’s robust and differentiated pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (“ADCs”), cytokines and T-cell engagers. CytomX’s clinical-stage pipeline includes varsetatug masetecan (Varseta-M; CX-2051) and CX-801. Varseta-M is a masked, conditionally activated ADC armed with a topoisomerase-1 inhibitor payload and directed toward epithelial cell adhesion molecule (EpCAM). EpCAM is a highly expressed tumor antigen that has previously been undruggable due to expression on normal tissues. Varseta-M is designed to open a therapeutic window for this high potential target and is initially being developed for the treatment of metastatic colorectal cancer. Varseta-M was discovered in collaboration with ImmunoGen, now part of AbbVie. CX-801 is a masked interferon alpha-2b PROBODY^® cytokine with broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors. CX-801 is initially being developed for the treatment of metastatic melanoma. CytomX has established strategic collaborations with multiple leaders in oncology, including Amgen, Regeneron and Moderna. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit www.cytomx.com and follow us on LinkedIn and X (formerly Twitter).

Company Contact:
Chris Ogden
SVP, Chief Financial Officer
cogden@cytomx.com

Investor Contact:
Precision AQ
Stephanie Ascher
stephanie.ascher@precisionaq.com

Media Contact:
Precision AQ
Colleen Ketchum
colleen.ketchum@precisionaq.com